China FeNO Testing Market Size, Share, Growth, Trends, and Forecast, 2030

China FeNO Testing Industry Prospective:

The China FeNo testing market size was worth around USD 23.08 million in 2022 and is predicted to grow to around USD 61.46 million by 2030 with a compound annual growth rate (CAGR) of roughly 13.02% between 2023 and 2030.

The report analyzes the China FeNo testing market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the China FeNo testing industry.

Request Free Sample

China FeNo Testing Market: Overview

FeNo stands for Fractional Exhaled Nitric Oxide. It is a medical term that is used to refer to the process of measuring nitric oxide (NO) levels in a person’s exhaled breath. NO is a gas that is produced by cells that exist in the lining of the airways. FeNO measurements can help in gaining more insights into the inflammation of the airway. When spoken in the context of respiratory health, FeNO testing is commonly used during the diagnosis, monitoring, and management of asthma which is a chronic respiratory condition that is characterized by inflammation and narrowing of the airways. During the testing process, the level of exhaled nitric oxide provides information on airway inflammation, particularly eosinophilic inflammation, which typically means that the person has contracted asthma. The industry deals with the economic and infrastructural aspects of FeNO testing across the Chinese province.

Key Insights:

• As per the analysis shared by our research analyst, the China FeNo testing market is estimated to grow annually at a CAGR of around 13.02% over the forecast period (2023-2030)
• In terms of revenue, the China FeNo testing market size was valued at around USD 23.08 million in 2022 and is projected to reach USD 61.46 million, by 2030.
• The China FeNo testing market is projected to grow at a significant rate due to the growing prevalence of asthma
• Based on indication segmentation, chronic respiratory symptoms was predicted to show maximum market share in the year 2022
• Based on distribution channel segmentation, the direct tender was the leading channel in 2022
• On the basis of region, Tier 1 regions were the leading revenue generator in 2022

China FeNo Testing Market: Growth Drivers

Growing prevalence of asthma to propel market growth

The China FeNO testing market is projected to grow owing to the rising prevalence of asthma in China. In recent years, the number of reported incidents of asthma has surged resulting in higher demand for FeNo testing. As per the National Institute of Health (NIH), asthma is a major public health concern in the country. More than 4.2% of the population which constitutes around 45 million people in China suffer from frequent asthmatic attacks. There are several factors why the rate has been growing in recent times. The foremost cause is related to environmental factors. China is witnessing a rapid rate of urbanization along with rampant industrialization leading to the general population getting increasingly exposed to environmental pollutants such as particulate matter, allergens, and indoor pollutants. Furthermore, air pollution in China has crossed record levels. Over the years, China has faced significant challenges related to air pollution, particularly in densely populated urban areas.

China FeNo Testing Market: Restraints

Cost and affordability to restrict market expansion

The high cost of FeNo testing could restrict regional market expansion. In addition to this, the expense associated with consumables could lead to a significant rise in overall healthcare expenditure. The affordability of FeNo testing remains a major roadblock for the China FeNo testing market. Although, as per reports, nearly 95% of the population has access to basic healthcare, severe cases of asthma may not be covered by these policies.

China FeNo Testing Market: Opportunities

Rising awareness rate to provide growth opportunities

The China FeNo testing industry is expected to benefit from the growing awareness rate about asthma and the availability of various testing methods among people. Increased awareness is expected to drive the demand for more cost-effective FeNO testing. Furthermore, the country has been witnessing a high economic growth rate. It is soon expected to become one of the world’s most advanced countries and this trend could work in the favor of the FeNo testing sector as more people get access to basic and advanced healthcare.

China FeNo Testing Market: Challenges

Lack of standard testing procedures to challenge the market expansion

The regional market is expected to face growth challenges owing to the lack of standard testing procedures and variations in testing practices. Furthermore, the China FeNo testing market is also plagued with differences in the interpretation of FeNO results among healthcare professionals which could become a cause of concern for the patients. Standardizing testing protocols, establishing clear guidelines, and promoting professional training and certification can help ensure consistency and accuracy in FeNO testing.

China FeNo Testing Market: Segmentation

The China FeNo testing market is segmented based on indication, type, distribution channel, end-user, and region.

Based on indication, the regional market is divided into chronic respiratory symptoms, eosinophilic airway inflammation, COPD with mixed inflammatory phenotype, atopic asthma, cystic fibrosis, pulmonary arterial hypertension, eosinophilic bronchitis, corticosteroid responsiveness, and others. The China FeNo testing industry witnessed the highest growth in the chronic respiratory symptoms segment, Asthma is typically characterized by frequent episodes of chronic respiratory symptoms. These symptoms tend to vary in intensity between patients. Eosinophilic airway inflammation is a very specific type of inflammation and occurs in the airways of individuals with certain respiratory conditions and one of them is asthma. Chronic obstructive pulmonary disease (COPD) with a mixed inflammatory phenotype is COPD characterized by the presence of both eosinophilic and neutrophilic inflammation in the airways. In recent times, China’s commercial health insurance premium income grew by 30%.

Based on type, the global market divisions are Nitric Oxide standalone monitors, nitric oxide handheld monitors, and others.

Based on distribution channel, the global market segments are retail sales, direct tender, and online sales. The China FeNo testing industry witnessed the highest growth in the direct tender segment in 2022 due to the majority of the hospitals collaborating with suppliers and manufacturers of FeNo testing kits. However, the online sales segment is expected to grow at a higher CAGR during the forecast period as compared to previous years due to the growing popularity of online sales in the healthcare sector. In recent times, China has registered surging growth in e-commerce and online platforms which also includes the sale of medical devices and diagnostics. There are several advantages associated with online purchases. During the projection period, factors such as convenience, accessibility, and growing digital infrastructure are projected to play a crucial role in segmental growth. As per research, China's online healthcare market in 2020 was close to 94 billion yuan.

Recent Developments:

• In March 2023, Shanghai Dongfang Hospital in China announced that it had managed to successfully implement the country’s first treatment process for refractory asthma. The hospital simultaneously also carried out pre-market clinical trials across 8 hospitals in the country
• In May 2019, XINHUANET reported that Chinese experts had called out for the standard treatment of patients with asthma. They claimed that out of 30 million asthma patients in the same year, only 5% had received proper treatment. They recommended that diagnosed patients wear masks at all times and maintain regular medication during flying catkins seasons
• In November 2019, PulmOne USA Inc. entered a partnership with Circassia Pharmaceuticals for offering NIOX VERO® fractional exhaled nitric oxide (FeNO) airway inflammation measurement system that comes along with PulmOne's MiniBox+. Circassia is a global pharmaceutical and medical device company with offices in China, the US, and other nations

China FeNo Testing Market: Report Scope

China FeNo Testing Market: Regional Analysis

China to witness a high growth rate during the forecast period

The China FeNo testing market is projected to grow rapidly owing to the increasing number of asthmatic patients in the Chinese province. Factors such as increased rates of air pollution and other environmental factors are leading causes of the rise in the asthmatic population. In addition to this, the Chinese chemical industry, which is also one of the world’s most dominant chemical industries, has resulted in addition to the already bad quality of air in this region. The highest growth rate may be observed in the Tier 1 cities of China. This includes regions such as Beijing, Shanghai, Guangzhou, and Shenzhen. The higher growth rate could be a result of the existence of a well-developed healthcare infrastructure and a higher concentration of specialized healthcare facilities. This segment is expected to provide more FeNo testing measures.

China FeNo Testing Market: Competitive Analysis

The China FeNo testing market is led by players like:

• Guangzhou Kingmed Diagnostics Group Co. Ltd.
• Hangzhou Clongene Biotech Co. Ltd.
• Shanghai Fosun Long March Medical Science Co. Ltd.
• Nanjing Norman Biological Technology Co. Ltd.
• Beijing Eastwest Harmony Medical Devices Co. Ltd.
• Guangzhou YERCON Diagnostic Co. Ltd.
• Aeonmed Co. Ltd.
• Haina Bio-Medical Technology Co. Ltd.
• Shanghai Hua An Medical Health Science Co. Ltd.
• Wuxi Medical Instrument Factory Co. Ltd.
• Shanghai Hengkang Medical Equipment Co. Ltd.
• Mindray Medical International Limited
• Nihon Kohden Corporation
• Edan Instruments Inc.
• Shenzhen Comen Medical Instruments Co. Ltd.
• Yuyue Medical Equipment & Supply Co. Ltd.
• Biolight Meditech Co. Ltd.
• Perlong Medical Equipment Co. Ltd.
• Beijing Choice Electronic Technology Co. Ltd.
• M&B Electronic Instruments Inc.
• Shenzhen Creative Industry Co. Ltd.
• Chindex Medical Limited
• Yantai Dongcheng Biochemicals Co. Ltd.
• Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
• Shenzhen Anke High-tech Co. Ltd.

The China FeNo testing market is segmented as follows:

By Indication

• Chronic Respiratory Symptoms
• Eosinophilic Airway Inflammation
• COPD with Mixed Inflammatory Phenotype
• Atopic Asthma
• Cystic Fibrosis
• Pulmonary Arterial Hypertension
• Eosinophilic Bronchitis
• Corticosteroid Responsiveness
• Others

By Type

• Nitric Oxide Standalone Monitor
• Nitric Oxide Handheld Monitor
• Others

By Distribution Channel

• Retail Sales
• Direct Tender
• Online Sales

By Region

• China